Elekta (OTCMKTS:EKTAY – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare Elekta to related businesses based on the strength of its earnings, risk, dividends, institutional ownership, profitability, analyst recommendations and valuation.
Institutional and Insider Ownership
40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 41.3% of Elekta shares are held by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Elekta and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Elekta | -2.38% | 13.47% | 3.84% |
| Elekta Competitors | -276.78% | -149.08% | -21.73% |
Volatility and Risk
Elekta has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Elekta’s peers have a beta of 2.57, indicating that their average stock price is 157% more volatile than the S&P 500.
Dividends
Elekta pays an annual dividend of $0.12 per share and has a dividend yield of 1.9%. Elekta pays out -100.0% of its earnings in the form of a dividend. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.1% and pay out 53.9% of their earnings in the form of a dividend.
Valuation and Earnings
This table compares Elekta and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Elekta | $1.78 billion | -$55.38 million | -51.33 |
| Elekta Competitors | $1.89 billion | $137.77 million | 9.07 |
Elekta’s peers have higher revenue and earnings than Elekta. Elekta is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Elekta and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Elekta | 0 | 1 | 0 | 0 | 2.00 |
| Elekta Competitors | 4270 | 10532 | 18290 | 828 | 2.46 |
As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 19.53%. Given Elekta’s peers stronger consensus rating and higher probable upside, analysts plainly believe Elekta has less favorable growth aspects than its peers.
Summary
Elekta peers beat Elekta on 9 of the 15 factors compared.
About Elekta
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.
